RxDoctor Payments Data

Scott Balogh, MD

Addiction Medicine · Cordova, TNNPI 1144462466

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 45.9% of the total. Reporting peaked in 2019 at $172 and has fallen 82.8% since, to $30 in 2025. That places this record below the midpoint for addiction medicine clinicians in TN, where the typical reported total is $404.

$405in general payments, 2019–2025

Across 18 payments — averaging $22.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$186
  • Indivior Inc.$140
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$41
  • Neuronetics, Inc.$39
$81,369in research payments, 2019–2025

Across 10 payments — averaging $8136.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$81K

What the payments were for

  • Food & beverage$405100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$405 in reported general payments places this provider in the 50th percentile of 76 addiction medicine providers in Tennessee.

See all addiction medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$51,623
Medicare patients
104
Services billed
437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl14$23,420
TrintellixVortioxetine Hydrobromide28$11,497
Aripiprazole70$4,891
Clozapine53$3,829
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl20$2,579
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine47$2,134
Carbamazepine33$1,777
Desvenlafaxine Succinate ErDesvenlafaxine Succinate31$1,540
Divalproex Sodium ErDivalproex Sodium45$1,346
Alprazolam48$1,278
Oxycodone Hcl32$1,004
Venlafaxine Hcl ErVenlafaxine Hcl28$992
Duloxetine Hcl41$827
Oxcarbazepine13$770
Buspirone Hcl17$662

Paid to pharmacies, not to this prescriber.

Other addiction medicine in Cordova

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →